ACKNOWLEDGEMENTS

We thank A Renneville, C Preudhomme (Lille), O Wagner-Ballon (Créteil) and E Solary (Villejuif) for helpful discussion, S Baulande from ICGex NGS platform of the Institut Curie and investigators of the Groupe Francophone des Myelodysplasies. This study received a research grant from Celine and was conducted by two teams labeled by the SIRIC Cancer Research for PERSONALIZED Medicine CARPEM. OK received a CARPEM fellowship grant.

REFERENCES

1 List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

2 Fenaux P, Giagounidis A, Sellestag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–3776.

3 Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasson A, Vey N et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol 2016; 34: 2988–2996.

4 Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R et al. Combined treatment with lenalidomide and epoetinalfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419–3424.

5 Toma A, Kosmider O, Chevret S, Delauyaj J, Stamatioulaas A, Rose C et al. Lenalidomide with or without erythropoiesis in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 2016; 30: 897–905.

6 Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PloS Med 2008; 5: e35.

7 Chernev I, Renneville A, Toma A, Lambert J, Passet M, Dumont F et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood 2016; 127: 749–760.

8 Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 2015; 523: 183–188.

9 Basioraka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. Cancer Res 2016; 76: 3531–3540.

10 McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia 2012; 26: 1425–1429.

11 Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA et al. The immunosupillary effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605–1613.

12 Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016; 17: 218.

13 Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5: 133–139.

14 Marnett JL, Shih I, Levine RJ, Tew KD. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011; 153: 568–581.

15 Sladden MJ, Mainwaring L, Fuhrer M, Ramkisson S, Ristina AM, Keyvanfar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 2982–2991.

16 Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppole GJ, Wessels TM, Bonnicksen HJ. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011; 153: 568–581.

17 Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Vivascent G, Bourhis JH et al. Cytoytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463–470.

OPEN

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

Leukemia (2018) 32, 562–565; doi:10.1038/leu.2017.306

Relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) is an aggressive malignant disease with poor prognosis and an unmet medical need. The prognosis is particularly dismal for adults with ALL who require second salvage therapy or children who require multiple salvage therapies after prior therapies have failed.1,2 Blinatumomab is a Bispecific T-cell Engager (BiTE) antibody construct that is designed to link T cells

Accepted article preview online 9 October 2017; advance online publication, 31 October 2017
Studies MT103-205 and MT103-206 included a dose-continuous infusion, followed by a 2-week treatment-free interval. In each of the three single-arm, open-label phase 2 studies, blinatumomab retreatment was permitted if a patient relapsed after an initial response to blinatumomab. The objective of this analysis was to evaluate the efficacy of blinatumomab retreatment in these patients. Study MT103-205 (NCT01471782; EudraCT 2010-024264-18) was a phase 1–2 study of 93 children and adolescents with B-precursor ALL that was in second or later bone marrow relapse (blast percentage $>25$), in relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT), or refractory to other treatments. Study MT103-206 (NCT01209286; EudraCT 2009-015989-62) was an exploratory phase 2 study of 36 adult patients with B-precursor relapsed/refractory ALL and $>5\%$ marrow blasts. Study MT103-211 (NCT01466179; EudraCT 2011-002257-61) was a confirmatory phase 2 study of 189 adult patients with Philadelphia chromosome-negative B-precursor ALL that was primary refractory, in early ($<12$ months) first relapse, in early relapse after alloHSCT, or in later relapse; patients with $\geq10\%$ marrow blasts were eligible. Key exclusion criteria in each study were alloHSCT in the previous 3 months, active graft-versus-host disease, or central nervous system involvement.

Each cycle consisted of 4 weeks of blinatumomab by continuous infusion, followed by a 2-week treatment-free interval. Studies MT103-205 and MT103-206 included a dose-finding part and the selected dose was defined by body surface area, with stepwise dosing of $5–15\,\mu g/m^2/d$ ($5\,\mu g/m^2/d$ in cycle 1 week 1 and $15\,\mu g/m^2/d$ thereafter). In Study MT103-211, all patients received stepwise fixed dosing of $9–28\,\mu g/d$ ($9\,\mu g/d$ in cycle 1 week 1 and $28\,\mu g/d$ thereafter). After each infusion period, bone marrow aspiration was performed to evaluate efficacy. Lumbar puncture was performed after bone marrow aspiration to evaluate central nervous system leukemic involvement and for the administration of intrathecal chemotherapy prior to start of blinatumomab and after each cycle.

Response criteria for each study are provided in Supplementary Table S1. Patients who achieved a remission within the first two cycles could receive up to three additional cycles of blinatumomab or alloHSCT instead of further blinatumomab treatment. If the patient experienced hematologic relapse during follow-up, up to three additional cycles of blinatumomab retreatment could be administered. For patients from Study MT103-205, retreatment was stepwise dosing of $5–15\,\mu g/m^2/d$. For patients from Studies MT103-206 and MT103-211, retreatment was administered with the patient’s original dosing schedule. Adverse events were recorded throughout initial treatment and retreatment. An Independent Ethics Committee or Institutional Review Board responsible for each site approved each of the study designs. Informed consent was obtained from all patients.

Eleven patients (seven male, four female) received blinatumomab retreatment after initial response and relapse. The median age of retreated patients was 25 years (range, 4–77); two were $<18$ years, eight were $18$ to $<65$ years, and one was $\geq65$ years. Before original study enrollment, these patients had experienced one ($n=5$), two ($n=4$), or three or more ($n=2$) prior relapses. Bone marrow blast infiltration before blinatumomab treatment was $>50\%$ for seven patients and $<50\%$ for four patients. The median duration of initial blinatumomab treatment for these 11 patients was 82 days (range, 1–150). The median duration of initial blinatumomab-induced response was 9.3 months (range, 3.5–12.4), and the median duration of the treatment-free period between initial treatment and

| Pt | Age | Study | Initial treatment | Intervening alloHSCT | Retreatment | Response | Response duration (months) | Grade $\geq3$ neurologic event | Blast at relapse | Best hematologic response | Overall survival (months) | Relapse-free survival (months) |
|----|-----|------|-------------------|----------------------|-------------|---------|----------------------------|-----------------------------|-----------------|---------------------------|-----------------------------|-------------------------------|
| 1  | 65  | 5     | 9–15 $\mu g/m^2$ | PD                   | No response | CR      | 3.7                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 2  | 66  | 6     | 5–15 $\mu g/m^2$ | No response          | PD           | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 3  | 67  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 4  | 68  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 5  | 69  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 6  | 70  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 7  | 71  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 8  | 72  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 9  | 73  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 10 | 74  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |
| 11 | 75  | 5     | 5–15 $\mu g/m^2$ | PD                   | No response | CR      | 12.5                        | 10%                         | Yes             | CR                        | 12.9                        | 20.0                          |

Abbreviations: —, not assessed; alloHSCT, allogeneic hematopoietic stem cell transplantation; CI, confidence interval; CR, complete remission; CRh, CR with partial hematologic recovery; PR, partial remission; RFS, relapse-free survival. *Age at initial treatment and relapse was not calculated for this patient because the initial response occurred after blinatumomab treatment ended.
retrieval with blinatumomab treatment was 6.6 months (range, 3.0–12.2). Between initial treatment and retreatment, nine patients were CD19-positive by flow cytometry, and one was CD19-positive by immuno-cytometry, and one had unknown CD19 status. The median duration of blinatumomab retreatment was 28 days (range, 4–85).

Clinical characteristics for individual patients are summarized in Table 1. Seven patients had received alloHSCT before initial blinatumomab treatment and six had received alloHSCT between blinatumomab treatment and retreatment. Between blinatumomab treatment and retreatment, one patient received chemotherapy (FLAG-IDA) followed by alloHSCT. One patient received blinatumomab retreatment twice. Three patients received additional systemic therapy after blinatumomab retreatment.

Four patients (36%) responded to retreatment, all in the first cycle. All four responders were adults and were CD19-positive: three by flow cytometry and one by immuno-cytometry. Median overall survival for all retreated patients was 9.4 months (95% confidence interval: 0.7, 12.9) from the start of blinatumomab retreatment (Supplementary Figure S1). Among the four responders to blinatumomab retreatment, overall survival after initiation of blinatumomab retreatment was 4.8 months for one patient and overall survival was censored at 3.7, 4.6, and 20.0 months, respectively, in the other three patients who were in ongoing survival at the time of data cutoff. Per the study designs, each of these patients achieved remission with blinatumomab retreatment as second or later salvage therapy for ALL.

Adverse events with blinatumomab retreatment (Table 2) were consistent with those reported with initial blinatumomab treatment.3–5 Three patients (27%) had grade ≥3 neurologic events during retreatment; all three patients also had neurologic events during initial blinatumomab treatment. A 77-year-old man in Study MT103-206 had grade 3 treatment-related encephalopathy with initial treatment that recurred with retreatment. Blinatumomab retreatment was discontinued and the event resolved. The patient achieved a partial remission with blinatumomab retreatment. A 21-year-old man in Study MT103-206 had grade 1 neurologic events in initial treatment that were not related to blinatumomab; grade 3 treatment-related epilepsy during blinatumomab retreatment resolved with permanent discontinuation of blinatumomab. The patient’s response to retreatment was not assessed. A 20-year-old woman in Study MT103-211 had grade 2 treatment-related disorientation with initial treatment and grade 3 paraplegia in retreatment that was not related and resolved with continued blinatumomab retreatment. The patient achieved a complete remission with blinatumomab retreatment. There were no reports of cytokine release syndrome with blinatumomab retreatment.

T-cell and B-cell kinetics during initial blinatumomab treatment and during blinatumomab retreatment were recorded for the five patients in Study MT103-206 (Supplementary Figure S2). In these patients, all of whom had complete remission, partial remission, or a hyporeactive response to blinatumomab retreatment, some T-cell expansion and sustained B-cell depletion were also observed with blinatumomab retreatment.

Blunt counts at the relapse that led to blinatumomab retreatment were recorded for four patients (Table 1): 10% before complete remission, 10% before partial remission, 10% before no response not assessed but overall survival of 12.3 months, and 93% before no response to treatment. The lack of response in the patient with 93% blast count is consistent with published demonstration of higher remission rates with initial blinatumomab treatment in patients with counts below 50% than in patients with counts of at least 50%, including both pediatric patients (56 versus 33%)3 and adult patients (73 versus 29%).5 As described above, grade ≥3 neurologic adverse events were observed with blinatumomab retreatment in three patients: two with related events and one with an unrelated event. The two patients with related neurologic events survived for more than 12 months. But information about blast counts and neurotoxicity in individual patients (Table 1) was not sufficiently informative and the sample size in this analysis was too small for definitive conclusions about patient-specific factors that predict response to blinatumomab retreatment. However, these results suggest that T-cell and B-cell kinetics, blast counts, and adverse events could be analyzed as possible predictors in a larger study of blinatumomab retreatment. Other patient-specific factors such as CD19 expression or expression of the programmed death receptor and its ligand (PD-1/PD-L1)7,8 were not recorded in these studies and could also be considered for future research.

In conclusion, this analysis showed that blinatumomab retreatment may be successful in patients with relapsed/refractory ALL and prior responses to blinatumomab, even among those who have an early CD19-positive relapse within 12 months. Despite the small sample size, the remission rate for blinatumomab retreatment in this analysis (36%) was similar to that recently reported for initial blinatumomab treatment in a large, randomized, phase 3 pivotal study (44%).6 These results suggest that blinatumomab retreatment is a reasonable intervention for relapse among patients who have responded to blinatumomab previously. Additional study of a larger population would be required to identify predictors of response to blinatumomab retreatment.

CONFLICT OF INTEREST

MST: Research support and/or consulting fees from Amgen, Roche, Regeneron, Affimed, Jazz, Gilead and Pfizer. MS: Research grants from Pfizer. Consulting fees from Amgen, Pfizer and Jazz. Speakers bureau for Amgen and Pfizer. GZ, JEB: Consulting fees from Amgen, Novartis, AstraZeneca, Pfizer, Genmab, GEMoA GmbH and Celllex. Patents/royalties for blinatumomab, CH: Employee and stockholder of Amgen. Stockholder of MacroGenics. MK: Employee and stockholder of Amgen. Inventor remuneration due to blinatumomab-related patent. MRL: Research grants from Amgen. The remaining authors declare no conflict of interest.

Table 2. Adverse events in >1 retreated patient overall, by age group

| Event                              | Adult (n = 9) | Children and Adolescents (n = 2) | All (N = 11) |
|------------------------------------|---------------|---------------------------------|--------------|
| Any adverse event                  |               |                                 |              |
| Pyrexia                            | 7 (78)        | 1 (50)                          | 8 (73)       |
| Diarrhea                           | 3 (33)        | 1 (50)                          | 4 (36)       |
| Leukopenia                         | 3 (33)        | 0 (0)                           | 3 (27)       |
| Neutropenia                        | 3 (33)        | 0 (0)                           | 3 (27)       |
| Thrombocytopenia                   | 3 (33)        | 0 (0)                           | 3 (27)       |
| Anemia                             | 2 (22)        | 0 (0)                           | 2 (18)       |
| Cough                              | 2 (22)        | 0 (0)                           | 2 (18)       |
| Epistaxis                          | 1 (11)        | 1 (50)                          | 2 (18)       |
| Fatigue                            | 2 (22)        | 0 (0)                           | 2 (18)       |
| Fever                              | 1 (11)        | 1 (50)                          | 2 (18)       |
| Weight decreased                   | 2 (22)        | 0 (0)                           | 2 (18)       |
| Weight increased                   | 2 (22)        | 0 (0)                           | 2 (18)       |
| Any adverse event, grade ≥ 3       | 7 (78)        | 1 (50)                          | 8 (73)       |

Neutropenia                         | 3 (33)        | 0 (0)                           | 3 (27)       |
| Thrombocytopenia                   | 3 (33)        | 0 (0)                           | 3 (27)       |
| Anemia                             | 2 (22)        | 0 (0)                           | 2 (18)       |
| Febrile neutropenia                | 1 (11)        | 1 (50)                          | 2 (18)       |
ACKNOWLEDGEMENTS
This study was supported by research funding from Amgen Inc, Geoff Smith of Amgen Inc. and Jonathan Latham, a medical writer supported by funding from Amgen Inc., provided editorial assistance to the authors during the preparation of this manuscript.

MS Topp1, M Stelljes2, G Zugmaier3, P Barnett4, LT Heffner Jr5, T Trippett3, J Duell1, RC Bargou6, C Holland4, JE Benjamin3,11, M Klinger3 and MR Litzow10
1 Medizinische Klinik und Poliklinik II, Universitätssklinikum Würzburg, Würzburg, Germany;
2 Hematology, Oncology and Pneumology, University of Münster, Münster, Germany;
3 Research and Development, Amgen Research (Munich) GmbH, Munich, Germany;
4 Pediatric Hematology/Oncology, Primary Children’s Hospital, Salt Lake City, UT, USA;
5 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA;
6 Memorial Sloan-Kettering Cancer Center, New York, NY, USA;
7 Comprehensive Cancer Center Mainfranken, University Hospital, Würzburg, Germany;
8 Research and Development, Amgen Inc., Washington, DC, USA;
9 Research and Development, Amgen Inc., Thousand Oaks, CA, USA and
10 Division of Hematology, Mayo Clinic, Rochester, MN, USA
E-mail: gerhardz@amgen.com
11 Former Amgen employee.

REFERENCES
1 O’Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113: 3186–3191.

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma

Leukemia (2018) 32, 565–569; doi:10.1038/leu.2017.309

Anaplastic large cell lymphomas (ALCLs) constitute a group of peripheral (that is, post-thymic) T-cell non-Hodgkin’s lymphomas (PTCLs) with overlapping pathologic characteristics, but varying clinical and molecular features. Specifically, ALCLs share cytological and immunophenotypic features, including consistent expression of the lymphocyte activation marker, CD30.1 The World Health Organization (WHO) classifies ALCLs by their clinical presentation (systemic or cutaneous) and whether or not they bear rearrangements of the anaplastic lymphoma kinase gene, ALK (ALK-positive ALCL and ALK-negative ALCL, respectively).2

ALK-positive ALCL is characterized by a unique gene expression signature that distinguishes it from ALK-negative ALCLs.3–5 ALK rearrangements have a broad spectrum of functional consequences, prominent among which is activation of the signal transduction protein STAT3 (signal transducer and activator of transcription 3).6 Analogously, STAT3 may be activated in ALK-negative ALCLs by somatic events involving non-ALK tyrosine kinase genes, including rearrangements of the TYK2 or ROS1 tyrosine kinase genes as well as mutations in JAK1 or STAT3 itself.7,8 However, the full spectrum of tyrosine kinases involved in ALK-negative ALCL pathogenesis and growth remains incompletely understood, as does the similarity of these events to the molecular signature identified in ALK-positive ALCLs. For example, a subclass of ALK-negative ALCLs expressing aberrant transcripts of the ERBB4 tyrosine kinase gene had a gene expression signature distinct from ALK-positive ALCLs.9

To evaluate the relationship between the gene expression profiles of ALK-positive and ALK-negative ALCLs, we performed expression profiling on 31 frozen ALCL tissue samples (Supplementary Table 1) using Affymetrix arrays (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and derived an ALK signature from our data set comprising the 29 probes most differentially expressed between these 2 groups (see Supplementary Methods for details). Clustering using this ALK signature identified a single ALK-negative case, ALCL11, that clustered with ALK-positive ALCLs (Figure 1a; P = 0.02, Kolmogorov–Smirnov test). The validity of the